All sample (N = 395) | Respondersa (N = 194) | No responders (N = 201) | P-value† | |
---|---|---|---|---|
Headache days/month | −11.3 ± 10.7 | −15.3 ± 10.2 | −7.4 ± 7.3 | < 0.0001 |
Moderate-severe headache days/month | −7.3 ± 7.0 | −8.5 ± 8.9 | −3.6 ± 8.1 | < 0.0001 |
≥50% headache days rate | 51.4% | 66.5% | 36.8% | < 0.0001 |
≥50% moderate-severe headache days rate | 54.2% | 70.6% | 38.3% | < 0.0001 |
Conversion to episodic migraine | 52.9% | 68.0% | 38.3% | < 0.0001 |
≥50% pain intensity reduction | 35.8% | 50.0% | 21.0% | < 0.0001 |
Acute treatment use (pills/month) | −24.9 ± 26.5 | −34.2 ± 52.7 | −14.1 ± 37.9 | < 0.0001 |
≥50% acute treatment reduction (pills/month) | 60.4% | 69.6% | 49.3% | < 0.0001 |
Conversion from medication overuse to non-medication overuse | 37.5% | 44.8% | 30.3% | 0.004 |
≥50% MIDAS score reduction rate | 49.1% | NA | NA | NA |